Nora Sandorfi, MD, Professor of Clinical Medicine, Rheumatology at the University of Pennsylvania, discusses patient sentiments regarding treatment options for warm autoimmune hemolytic anemia (wAIHA).

 


 

wAIHA is a rare, autoimmune disorder in which various auto-antibodies are directed against red blood cells and resulting in hemolytic anemia. Typical management for this condition includes immunosuppressive and anti-CD20 B cell depleting therapies, such as rituximab, and blood transfusions. 

Dr. Sandorfi described her study aimed to explore the patient perspective and sentiment of treatment options available for those with wAIHA. Artificial intelligence (AI) was used to analyze digital conversations between patients over a 24-month period and assess the tone. The analysis specifically focused on conversations regarding treatment with rituximab or transfusion.

Among the conversations focused on rituximab treatment, 5% were deemed positive, 38% were negative, and 57% were neutral. Among conversations about treatment with transfusion, 0% were positive, 57% were negative, and 43% were neutral. The most common topics for conversations with a negative sentiment for both treatment options were lack of treatment efficacy and side effects.

Additionally, negative sentiment conversations were most common in patients in the treatment or treatment adjustment phase. Among those with neutral sentiments, most conversations were information seeking regarding treatment and therapies.

The results of this analysis offer a useful insight into patient perspectives of treatment options for wAIHA. Highlighted within this study is the importance of healthcare practitioners to implement treatment strategies that are supportive and take into account patient concerns and sentiment.

For more information, click here.

To learn more about wAIHA and other rare autoimmune conditions, visit https://checkrare.com/diseases/autoimmune-and-auto-inflammatory-disorders/

 

 

Nora Sandorfi, MD, Professor of Clinical Medicine, Rheumatology at the University of Pennsylvania, discusses patient sentiments regarding treatment options for warm autoimmune hemolytic anemia (wAIHA).

 


 

wAIHA is a rare, autoimmune disorder in which various auto-antibodies are directed against red blood cells and resulting in hemolytic anemia. Typical management for this condition includes immunosuppressive and anti-CD20 B cell depleting therapies, such as rituximab, and blood transfusions. 

Dr. Sandorfi described her study aimed to explore the patient perspective and sentiment of treatment options available for those with wAIHA. Artificial intelligence (AI) was used to analyze digital conversations between patients over a 24-month period and assess the tone. The analysis specifically focused on conversations regarding treatment with rituximab or transfusion.

Among the conversations focused on rituximab treatment, 5% were deemed positive, 38% were negative, and 57% were neutral. Among conversations about treatment with transfusion, 0% were positive, 57% were negative, and 43% were neutral. The most common topics for conversations with a negative sentiment for both treatment options were lack of treatment efficacy and side effects.

Additionally, negative sentiment conversations were most common in patients in the treatment or treatment adjustment phase. Among those with neutral sentiments, most conversations were information seeking regarding treatment and therapies.

The results of this analysis offer a useful insight into patient perspectives of treatment options for wAIHA. Highlighted within this study is the importance of healthcare practitioners to implement treatment strategies that are supportive and take into account patient concerns and sentiment.

For more information, click here.

To learn more about wAIHA and other rare autoimmune conditions, visit https://checkrare.com/diseases/autoimmune-and-auto-inflammatory-disorders/